Table 1.
PPA and NPA of commercial serology platforms with patients who were SARS-CoV-2 PCR positive.
| Positive percentage agreement (PPA) | ||||
|---|---|---|---|---|
| SARS-CoV-2 PCR (<15 days post-PCR positive) n = 25 | ||||
| Metric | Roche S | Roche N | Diazyme IgG | Diazyme NAbs |
| PCR positive | 25 | 25 | 25 | 25 |
| Positive on assay | 22 | 21 | 21 | 20 |
| PPA | 88.0% | 84.0% | 84.0% | 80.0% |
| Positive percentage agreement (PPA) | ||||
| SARS-CoV-2 PCR (≥15 days post-PCR positive) n = 28 | ||||
| Metric | Roche S | Roche N | Diazyme IgG | Diazyme NAbs |
| PCR positive | 28 | 28 | 28 | 28 |
| Positive on assay | 28 | 28 | 28 | 28 |
| PPA | 100.0% | 100.0% | 100.0% | 100.0% |
| Negative percentage agreement (NPA) | ||||
| 2018 samples (n = 116) and other respiratory pathogens (n = 11) | ||||
| Metric | Roche S | Roche N | Diazyme IgG | Diazyme NAbs |
| COVID-19 negative | 127 | 127 | 127 | 127 |
| Positive on assay | 0 | 1 | 0 | 2 |
| NPA | 100.0% | 99.2% | 100.0% | 98.4% |